Bullish
Amgen Inc. reported strong first-quarter 2026 results, surpassing revenue expectations with $8.3 billion, a 12% increase year-over-year, driven by top...
Bearish
The FDA's Center for Drug Evaluation and Research has proposed the withdrawal of Amgen's drug Tavneos, citing concerns about untrue statements of mate...
Neutral
Biotech company Amgen (NASDAQ:AMGN) is set to report its Q1 earnings, with market expectations for a 4.3% year-on-year revenue growth. Amgen beat reve...
Neutral
Amgen Inc. (NASDAQ: AMGN) is highlighted as a top stem cell therapy stock, following Canaccord's initiation of coverage with a Hold rating and a $366 ...
Neutral
Analysts have issued a "Hold" consensus rating for Amgen Inc. (NASDAQ:AMGN) from 31 research firms, with an average 12-month target price of $356.62. ...
Neutral
This article identifies five top stem cell therapy stocks for investors to consider, elaborating on the methodology in an extended list. It highlights...
Neutral
China Universal Asset Management Co. Ltd. grew its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 10.7% in the 4th quarter, according to its most ...
Neutral
The biologics market, valued at USD 629.97 billion in 2025, is projected to reach USD 1451.79 billion by 2033, growing at a CAGR of 11% due to increas...
Neutral
Amgen Inc. is positioned for growth due to its strong rare disease portfolio and its emerging obesity treatment, MariTide. While the company's core bu...
Neutral
Amgen Inc. has filed an SEC document for an offering of common stock by selling security holders, aimed at providing liquidity for these shareholders....
Bullish
Amgen Inc. is highlighted as a biotech leader with a robust pipeline, particularly in metabolic diseases like obesity, positioning it for growth in th...
Neutral
Blue Fin Capital Inc. lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 24.8% during the 4th quarter, according to its most r...
Neutral
Amgen Inc. is positioned for growth due to its strong rare disease pipeline and an emerging obesity drug, MariTide. While the company enjoys stable re...
Bullish
UBS analyst Michael Yee has reiterated a 'Buy' rating for Amgen (AMGN) and increased the price target from $390 to $400, signaling positive expectatio...
Bullish
Amgen Inc. and BeOne Medicines AG have received approval in China for tarlatamab, a new small cell lung cancer drug for adults whose tumors progressed...
This article analyzes Amgen (AMGN) after a recent 4.6% share price pullback, suggesting it may be undervalued. Using a Discounted Cash Flow (DCF) mode...